购物车
全部删除
您的购物车当前为空
别名 N-[4-乙酰基-2-(2,4-二氟苯氧基)苯基]-甲烷磺酰胺, FK-3311, COX-2 Inhibitor V
FK 3311 (COX-2 Inhibitor V) 是一种细胞渗透性和口服磺胺类药物,可作为 COX-2 抑制剂和非甾体抗炎药。


为众多的药物研发团队赋能,
让新药发现更简单!
FK 3311 (COX-2 Inhibitor V) 是一种细胞渗透性和口服磺胺类药物,可作为 COX-2 抑制剂和非甾体抗炎药。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 141 | 现货 | |
| 5 mg | ¥ 325 | 现货 | |
| 10 mg | ¥ 520 | 现货 | |
| 25 mg | ¥ 888 | 现货 | |
| 50 mg | ¥ 1,360 | 现货 | |
| 100 mg | ¥ 2,020 | 现货 | |
| 200 mg | ¥ 2,910 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 238 | 现货 |
FK 3311 相关产品
| 产品描述 | FK 3311 (COX-2 Inhibitor V) is a cell permeable and orally available sulfonanilide that acts as a COX-2 inhibitor and non-steroidal anti-inflammatory drug (NSAID) |
| 体内活性 | 在FK3311(FK)高剂量组中,存活率显著提高(p<0.05),复灌后30分钟的血清GOT水平显著降低(p<0.05)。复灌4小时后,该组的GPT水平和肝组织流量明显优于对照组(p<0.05)。无论是复灌后30分钟还是4小时,FK高剂量组的血清TxB(2)水平与对照组相比均显著降低(p<0.05)[1]。 |
| 动物实验 | Inbred male Lewis rats weighing 200-260 g were used. The donor liver was perfused with cold University of Wisconsin (UW) solution and then stored in the same solution at 4 degrees C for 18 hr. After the preservation period, orthotopic liver transplantation was performed. Animals were divided into three groups: the control group; the FK low-dose group (1 mg/kg FK3311 i.v. 20 min before reperfusion); and the FK high-dose group (3 mg/kg FK3311. 20 min before reperfusion). Survival rate, serum GOT and GPT levels, liver tissue blood flow, and serum thromboxane B(2) (TxB(2)) levels were compared among groups[1]. |
| 别名 | N-[4-乙酰基-2-(2,4-二氟苯氧基)苯基]-甲烷磺酰胺, FK-3311, COX-2 Inhibitor V |
| 分子量 | 341.33 |
| 分子式 | C15H13F2NO4S |
| CAS No. | 116686-15-8 |
| Smiles | CC(=O)c1ccc(NS(C)(=O)=O)c(Oc2ccc(F)cc2F)c1 |
| 密度 | 1.419g/cm3 |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (292.97 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (11.72 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容